COMMUNIQUÉS West-GlobeNewswire

Assertio Therapeutics Announces Submission of NDA for FDA Approval of Cosyntropin Depot

20/12/2018 - 15:00

-- Submission Advances Company’s Strategy to Build A New Orphan/Specialty Business and Aligns with Company’s Mission of Putting Patients First -- LAKE FOREST, Ill., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Assertio [...]

WATS3D Markedly Improves Detection of Esophageal Dysplasia and Barrett’s Esophagus in 12,899 Patient Study in the “Real World” Practice setting of 58 Community-Based Gastroenterologists

20/12/2018 - 15:00

- New Study with Largest Data Set to Date Demonstrates that Adjunctive Use of WATS 3D Significantly Increases Detection of Esophageal Precancer - - Study Published in Diseases of the Esophagus - SUFFERN, N.Y., Dec. 20, [...]

CV Sciences, Inc. to Present at Biotech Showcase™ Investor Conference on January 7th in San Francisco

20/12/2018 - 14:45

The Company’s executive team to meet with investors at one of industry’s largest annual healthcare conferences LAS VEGAS, Dec. 20, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB: CVSI) preeminent supplier and [...]

Matinas BioPharma to Present at Biotech Showcase 2019

20/12/2018 - 14:35

– Presentation with live audio webcast Monday, January 7th at 3:30 PM PST – BEDMINSTER, N.J., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical [...]

Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

20/12/2018 - 14:30

NEW YORK, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell ( [...]

Galectin Therapeutics Announces Extension of $10 Million Line Credit

20/12/2018 - 14:30

NORCROSS, Ga., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that its $10 million unsecured line of [...]

Assure Holdings Appoints Dr. Christopher Rumana to its Board of Directors

20/12/2018 - 14:30

DENVER, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “ Company ” or “ Assure ”) (TSXV: IOM; OTCPK: ARHH), a provider of intraoperative neuromonitoring services, has appointed Dr. Christopher Rumana to [...]

Adverum to Present at the 37th Annual J.P. Morgan Healthcare Conference

20/12/2018 - 14:30

MENLO PARK, Calif., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced [...]

Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53

20/12/2018 - 14:30

-- Golodirsen has been studied for the treatment of exon 53 amenable patients, approximately eight percent of patients with Duchenne -- -- Submission represents ongoing advancement of the company’s proprietary PMO RNA- [...]

Director/PDMR Shareholding

20/12/2018 - 14:00

Director/PDMR Shareholding 20 December, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) Notification of transactions by persons discharging managerial responsibilities 1. Details of the person discharging managerial [...]

Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia

20/12/2018 - 14:00

LAVAL, Québec, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of [...]

Synthorx Appoints Andrew Powell, J.D., to its Board of Directors

20/12/2018 - 14:00

Pratik Shah., Ph.D., Appointed Chairman of the Board SAN DIEGO, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform [...]

NORTHBUD Amends Licence Application to Add 500K SQ. FT. of Outdoor Cultivation Area and Provides a Corporate Update

20/12/2018 - 14:00

TORONTO, Dec. 20, 2018 (GLOBE NEWSWIRE) -- North Bud Farms Inc. (CSE: NBUD) ("NORTHBUD" or the "Company") announced the amendment of its licence application to add 500K SQ. FT. of outdoor cultivation area and provides [...]

VBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine Candidate

20/12/2018 - 14:00

CAMBRIDGE, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today [...]

CytomX Therapeutics Announces Changes to its Board of Directors

20/12/2018 - 14:00

- President and CEO Sean McCarthy, D. Phil., Appointed to Additional Role of Chairman - - Hoyoung Huh, M.D., Ph.D. Retiring from Board - - James R. Meyers, Former EVP at Gilead Sciences, Appointed to Board - SOUTH SAN [...]

Replimune to Present at the 37th Annual J.P.Morgan Healthcare Conference

20/12/2018 - 14:00

WOBURN, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced that Robert Coffin [...]

Cue Biopharma and LG Chem Life Sciences Announce WT1 as the Next Immuno-STAT™ Target in Oncology

20/12/2018 - 14:00

WT1 is a Well-Characterized Oncofetal Antigen, Expressed in Solid Tumors and Hematologic Malignancies CAMBRIDGE, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma ™, Inc., (NASDAQ: CUE) an innovative immunotherapy [...]

Retrophin Completes Enrollment of Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN

20/12/2018 - 14:00

Top-line data anticipated in the third quarter of 2019 SAN DIEGO, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced completion of patient enrollment in the pivotal Phase 3 FORT Study, [...]

Pascal Biosciences Provides Year-End Investor Update and Reviews Upcoming Milestones

20/12/2018 - 14:00

- 2018 pipeline expansion includes lead cannabinoid-based cancer therapeutic - Clinical trial in glioblastoma to begin in 2019 VANCOUVER, British Columbia and SEATTLE, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Pascal [...]